442 results about "Nervous system disease" patented technology

The invention discloses a probe set for detecting whole exons of extended genetic diseases. The probe set for detecting the whole exons of the extended genetic diseases comprises a standard whole exonprobe set, a whole genome copy number variation probe, and a mitochondrial loop full-length probe, and the genetic diseases comprise 6161 genetic diseases; the standard whole exon probe set can detect the genetic diseases caused by whole exon mutation, the genetic diseases comprise nervous system diseases, metabolic system diseases, endocrine system diseases, digestive system diseases, skeletal system diseases, urinary system diseases, immune system diseases, cardiovascular system diseases, blood system diseases, integument system diseases, ophthalmic system diseases, ear system diseases, respiratory system diseases, and genital system diseases; and the density of the mitochondrial probe is 6X; test samples comprise blood, fresh tissue, FFPE samples, and saliva. The invention discloses using method and kit and application of the probe set for detecting the whole exons of the extended genetic diseases.

The present invention relates to antibodies and related molecules that specifically bind to the Nogo receptor (NogoR). Such antibodies have uses, for example, in the treatment of spinal cord injury, brain trauma, paralysis, degenerative nervous system diseases, and stroke. The invention also relates to nucleic acid molecules encoding anti-NogoR antibodies, vectors and host cells containing these nucleic acids, and methods for producing the same.

The present invention relates to antibodies and related molecules that specifically bind to the Nogo receptor (NogoR). Such antibodies have uses, for example, in the treatment of spinal cord injury, brain trauma, paralysis, degenerative nervous system diseases, and stroke. The invention also relates to nucleic acid molecules encoding anti-NogoR antibodies, vectors and host cells containing these nucleic acids, and methods for producing the same.

[PROBLEMS]

To provide a compound useful as an agent for the treatment of circulatory diseases, nervous system diseases, metabolic diseases, reproductive system diseases, and digestive tract diseases.

[MEANS FOR SOLVING PROBLEMS]

The compound, which is for use as an active ingredient, is represented by the formula (I):

[wherein R¹ represents optionally halogenated C_1-6 alkyl, etc.; R² represents, e.g., a group represented by the formula (II-1) or (II-4)

(wherein W represents C_1-6 alkylene, etc. and R represents C_1-6 alkyl, etc.); R³ represents hydrogen, C_1-6 alkyl, etc.; X represents —O—, —NH—, etc.; and Y₁, Y₂, Y₃, and Y₄ each independently represents —CH—, —N—, etc.].

The present invention provides a method for the determining the appropriate therapy and/or prognosis for a patient diagnosed with a non-Alzheimer's disease (AD) neurological disease based upon the patient's apoE allele load. The invention also provides a method for the identification of human subjects with a non-AD neurological disease that are likely to respond in clinical trials that test pharmaceuticals useful in the treatment of neurological diseases.

The invention provides a triage method and system for a nervous system disease. The method provided by the invention comprises the steps: 1, carrying out the preprocessing of text data in a hospital electronic medical record, and extracting the symptoms and diagnostic data; 2, selecting the nervous system disease data for classification through a Bayes algorithm, and constructing a dedicated corpus; 3, constructing a training model based on a genetic algorithm, and carrying out the instructed learning of a training corpus; 4, modeling the classification after training, and constructing a triage knowledge graph of the nervous system disease.

The invention provides a method for constructing KARS-gene-mutated mouse models and application of the KARS-gene-mutated mouse models. The method for constructing the KARS-gene-mutated mouse models comprises the following steps: (1) carrying out target point construction: looking for a gene corresponding to nervous system diseases, and carrying out target point design; (2) designing Guide-RNA/Cas9mRNA, preparing plasmid, carrying out transcription, and then, injecting a transcription product into cytoplasm of a fertilized egg in a microinjection manner; (3) carrying out Founder mouse identification; (4) carrying out F1 mouse identification. According to the method for constructing the mouse models with the nervous system diseases and the application of the mouse models, provided by the invention, site-directed mutagenesis aiming at a KARS gene is carried out, so that a disease research on the model mice can be carried out under the condition of being closer to the occurrence and development of actual diseases, and a research result has a higher reference value.

The invention discloses application of eucommia ulmoides extracts in the preparation of compositions for tranquilizing and inducing sleep and application of the eucommia ulmoides extracts in the preparation of compositions for treating insomnia, anxiety neurosis or convulsion. The eucommia ulmoides extracts are continuously extracted from eucommia bark, eucommia leaves, eucommia male flowers and\or eucommia whole plants by petroleum ether, ethyl acetate, normal butanol, ethanol and water. The eucommia ulmoides extracts are obtained by extracting from eucommia plants. And results of researcheson the application of the eucommia ulmoides extracts in the field of tranquilization and sleep induction show that the eucommia ulmoides extracts have remarkable effects of tranquilizing and inducingsleep and resisting convulsion, wherein the ethyl acetate extract of eucommia and the normal butanol extract of the eucommia have more obvious effects. The eucommia ulmoides extracts are natural active materials for researching and developing novel health-care foods and new drugs for tranquilizing and inducing sleep, and can be applied to the treatment of nervous system diseases such as insomnia,anxiety neurosis and convulsion without side effects and psychic dependence.

The invention is directed to methods for treating nervous system injury and disease, in particular traumatic brain injury and degenerative nervous system disease. Such methods utilize novel compositions, including but not limited to trophic factor-secreting extraembryonic cells (herein referred to as TSE cells), including, but not limited to, amnion-derived multipotent progenitor cells (herein referred to as AMP cells) and conditioned media derived therefrom (herein referred to as amnion-derived cellular cytokine solution or ACCS), each alone or in combination with each other and/or other agents.

The invention relates to medical application of protopanaxa-triol (PPT), protopanaxadiol (PPD) and mixtures of the PPT and the PPD in any proportion in nervous system diseases, which are preferably used for treating and/or preventing epilepsy, cerebral ischemic diseases, memory disorder and parkinsonism syndrome.

The invention belongs to the field of pharmaceuticals and relates to a cascade brain-targeting drug delivery system and the application thereof. The cascade brain-targeting drug delivery system comprises a first-stage target functional molecule, a second-stage target functional molecule and a drug carrier. The cascade target drug delivery system can identify the blood-brain barrier through the first-stage target functional molecule and identify a brain lesion through the second-stage target functional molecule, so as to achieve the accurate targeting purpose, and can also accurately transfer imaging molecules or drugs to the brain lesion, so as to achieve good imaging and therapeutic effects. The cascade brain-targeting drug delivery system can be applied to prepare formulations for treatment or diagnosis of brain diseases (such as brain tumors) and nervous system diseases.

A method for designing and synthesizing 7-azaindirubin and 7-azaisoindigo derivative and its medicinal use are disclosed. It changes indirubin and isoindigo nuclear-parent molecule atomic composition to form into compound. It also changes original molecule electric property. The process is carried out by coupling at different position by 7-azaindole and indole bi-molecule, inhibiting CDKs and CDKIs growth and breed and inducing CDKIs biological function. It can be used to treat malignant tumor, HIV and nervous system diseases.

Conventional pupil detection equipment cannot realize simulation of different lighting environments, and the detection equipment with a darkroom environment has a large size and is extremely poor in convenience. The invention discloses wearable pupil light reflex measurement equipment. The lighting of different environments is simulated by a supplementary lighting light source by wearing a helmet on an examinee, and video data of both eyes of the examinee is captured by an infrared camera and is transmitted into a pupil measurement software system to realize analysis such as examine pupil aperture size measurement, iris area measurement and pupil aperture change curve drawing so as to obtain a screening result of a nervous system disease and form a clinical report. According to the equipment, the working intensity of a clinical medical worker can be greatly relieved, the precision of pupil reflex diagnosis is improved, and the equipment is extremely suitable for medical application in related fields such as clinical ophthalmology, neurosurgery and psychiatric and psychological department.

The invention relates to a dispersible tablet containing oryzanol for treating neurological system diseases and its preparing process, wherein the tablet comprises (by weight parts): oryzanol 5-200, filling agent 20-200, crumbling agent 15-40, bonding agent 1-70, flowing adjuvant or lubricating agent 0-5.

The invention discloses a preparation method of a brain tissue rapid freezing section. According to the method, acetone is used as a freezing embedding medium and a liquid nitrogen intermediate medium, so that brain tissue can be rapidly frozen , and formation of ice crystals on the brain tissue can be effectively reduced; besides, factors affecting manufacturing quality, such as temperatures during material drawing and sectioning, fixing and soring conditions after sectioning and the like, of the freezing section are optimized, and the quality of the finally prepared section is further guaranteed. According to the brain tissue rapid freezing section obtained with the method, the freezing section which has stability and can well protect antigens and the enzyme activity is provided for further immunofluorescence, immunohistochemistry and in situ hybridization tests on the brain tissue, and a pathological section meeting requirements is provided for future clinical diagnosis related to nervous system diseases and scientific researches. Particularly, molecular and biochemical index detection can be further performed on other tissue of a mouse which is not subjected to perfusion treatment in the scientific research.

The present invention is drawn to methods of characterization of the properties and functions of SV2 proteins. The invention further includes methods of identifying compounds or agents which modulate the activity of SV2 proteins. Included in these methods is the identification of compounds or agents which modulate the binding of levetiracetam to SV2 proteins, including SV2A. Additionally, the present invention provides biotinylated ligands as a tool to screen chemical libraries and characterize the SV2 proteins. Further, the present invention provides a method of solubilizing and purifying functionally active membrane associated proteins, such as SV2.

The invention belongs to the field of cytobiology and neurobiology, and provides an establishment method and application of a clinical-grade neural stem cell line. The method under GMP (Good Manufacturing Practice) control comprises two steps, namely, primary culturing of neural stem cells, and subculturing of neural stem cells. The identification result shows that the neural stem cell line established by the method can express a plurality of stem cell markers, can be differentiated into nerve cells, astrocyte and oligodendrocyte, has high stability, and is suitable for long-term culturing; a large amount of sufficient clinical-grade neural stem cells can be obtained by the method. The method can be used for establishing the neural stem cell line based on a plurality of neural stem cells and even single neural stem cell, and thus the error in study can be reduced as far as possible. By adopting the neural stem cell line established by the method and the cells obtained by differentiating the neural stem cell line, the problems of the safety and effectiveness risk in cell therapy of nervous system disease can be solved effectively, and safe and effective treatment on such diseases becomes possible.

The invention discloses a new secretive cytokine NS128 of human beings, which relates to a coding amino acid sequence of the cytokine or the polynucleotide of the cytokine fragment, containing a genetic engineering carrier and a host cell of the polynucleotide. The invention also relates to a production method of the amino acid sequence of the cytokine or the polypeptide of the cytokine fragment and the production method of the polypeptide as well as a small interference RNA, which suppresses the expression of the cytokine. The invention also relates to a salt which contains the polynucleotide or the salt of acceptable drugs, or a medical composition of the polypeptide or the salt of acceptable drugs. The invention further relates to applications of the polynucleotide of the cytokine, the polypeptide or the small interference RNA in preparation of prevention and/or treatment medicines for tumor, infection, hematopoietic disorder and autoimmune disease, etc., in particular having clinical implications for tumor, inflammation and nervous system disease and so on related to MAPK signal pathway. The invention also relates to a method of in vitro testing whether the expression of the polynucleotide or the polypeptide changes. The invention also relates to a monoclonal or polyclonal antibody which is specifically bound with the polypeptide or an active fragment of the polypeptide.